SEARCH

SEARCH BY CITATION

References

  • 1
    Centers for Disease Control and Prevention (CDC). Statistics: Prevalence of diabetes in the U.S. http://www.cdc.gov/diabetes/pubs/pdf/DiabetesReportCard.pdf (accessed 1 January 2013).
  • 2
    Centers for Disease Control and Prevention (CDC). Asthma prevalence, health care use, and mortality, 2000–2001; http://www.cdc.gov/nchs/products/ pibs/pubd/hestats/asthma/asthma.htm (accessed 1 April 2007).
  • 3
    Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:64657.
  • 4
    World Health Organization (WHO). World Heath Report 2001. Mental health: new understanding, new hope. Geneva, Switzerland: WHO Library Cataloguing in Publication Data, 2001.
  • 5
    Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:63845.
  • 6
    Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002;58:88594.
  • 7
    Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964;1:12369.
  • 8
    Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:69599.
  • 9
    Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:3351.
  • 10
    Dodick DW, Freitag F, Banks J et al. CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:54259.
  • 11
    Freitag FG, Collins SD, Carlson HA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:16529.
  • 12
    Freitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in the long-term treatment of chronic daily headache. Headache 2001;41:2718.
  • 13
    Mitsikostas DD, Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: a randomized, double open, clinical trial. Funct Neurol 1997;12:26776.
  • 14
    Bartolini M, Silvestrini M, Taffi R et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28:2779.
  • 15
    Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004;24:1160.
  • 16
    Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:814.
  • 17
    Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44:64751.
  • 18
    Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008;9:3741.
  • 19
    Mathew NT, Saper JR, Silberstein SD et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:2816.
  • 20
    Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997;54:11415.
  • 21
    Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:1038.
    Direct Link:
  • 22
    Apostol G, Cady RK, Laforet GA et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 2008;48:101225.
  • 23
    Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:6428.
  • 24
    Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:82530.
  • 25
    Shahien R, Saleh SA, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand 2011;123:25765.
  • 26
    Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491512.
  • 27
    Rall TW, Schleifer LS. Drugs effective in the therapy of epilepsies. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 8th edn. New York: Pergamon Press, 1990;43662.
  • 28
    van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia 2002;22:26570.
  • 29
    Lake AE 3rd. Placebo, chronic daily headache, and pain: ten points to ponder. Curr Pain Headache Rep 2006;10:46.
  • 30
    Dodick DW, Turkel CC, DeGryse RE et al. on behalf of the PREEMPT Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:92136.